Article · Wikipedia archive · Last revised Jul 20, 2026

Crisugabalin

Crisugabalin (HSK16149) is a novel GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathy with neuropathic pain and approved in July 2024 for the treatment of postherpetic neuralgia. In the United States, it is in Phase III trials as of 2023. The drug can be administered with or without food.

Last revised
Jul 20, 2026
Read time
≈ 1 min
Length
303 w
Citations
5
Source
Wikipedia ↗
Crisugabalin
Legal status
Legal status
Identifiers
  • 2-[(1S,2S,3R,6S,8S)-2-(aminomethyl)-2-tricyclo[4.2.1.03,8]nonanyl]acetic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC12H19NO2
Molar mass209.289 g·mol−1
3D model (JSmol)
  • C1C[C@@H]2[C@@H]3C[C@H]1C[C@@H]3[C@@]2(CC(=O)O)CN
  • InChI=1S/C12H19NO2/c13-6-12(5-11(14)15)9-2-1-7-3-8(9)10(12)4-7/h7-10H,1-6,13H2,(H,14,15)/t7-,8-,9+,10-,12-/m0/s1
  • Key:WCEFMBSFXJUREW-LIJGXYGRSA-N

Crisugabalin (HSK16149) is a novel GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathy with neuropathic pain1 and approved in July 2024 for the treatment of postherpetic neuralgia.2 In the United States, it is in Phase III trials as of 2023.34 The drug can be administered with or without food.5

See also

See also

References

References

  1. "Monthly Report: New Drug Approval in China, May 2024".
  2. "海思科苯磺酸克利加巴林胶囊获批新适应症". PhIRDA. 19 July 2024. Retrieved 26 April 2025.
  3. Gou, Xiaoli; Yu, Xiaojuan; Bai, Dongdong; Tan, Bowei; Cao, Pingfeng; Qian, Meilin; Zheng, Xiaoxiao; Chen, Lei; Shi, Zongjun; Li, Yao; Ye, Fei; Liang, Yong; Ni, Jia (March 2021). "Pharmacology and Mechanism of Action of HSK16149, a Selective Ligand of α2δ Subunit of Voltage-Gated Calcium Channel with Analgesic Activity in Animal Models of Chronic Pain". The Journal of Pharmacology and Experimental Therapeutics. 376 (3): 330–337. doi:10.1124/jpet.120.000315. ISSN 1521-0103. PMID 33293377.
  4. Guo, Xiaohui; Zhang, Tingting; Yuan, Geheng; Yukun, LI; Hua Ma, Jian; Hong-Mei, LI (2023). "224-OR: The Efficacy and Safety of HSK 16149 in Chinese with Diabetic Peripheral Neuropathic Pain—A Randomized, Double-Blinded, Placebo and Pregabalin-Controlled Phase II/III Study". Diabetes. 72 224-OR. doi:10.2337/db23-224-OR.
  5. Wu, Qingqing; Zhu, Huijuan; Song, Rong; Zhang, Mengqi; Li, Fangqiong; Zeng, Weifang; Wang, Wei; Jia, Jingying; Yu, Chen; Liu, Yanmei (June 2023). "Effect of a high-fat and high-calorie food on the pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy subjects". Pharmacology Research & Perspectives. 11 (3): e01102. doi:10.1002/prp2.1102. PMC 10199234. PMID 37208866.